Oncostatin M mediates the causal relationship between obesity and chronic kidney disease: evidence from Mendelian randomization and experimental validation
Zhang X., Tian Y., Ren X., Liu J., Wang G.
Animal Study on Chronic Kidney Disease, published in Diabetol Metab Syndr (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Diabetol Metab Syndr (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41340158
- PMCID
- PMC12676836
- DOI
- 10.1186/s13098-025-02010-1
Abstract (original English)
BACKGROUND: Obesity is a risk factor for chronic kidney disease (CKD). One of the main features of obesity-related glomerulopathy (ORG) is the chronic low-grade inflammatory state. Herein, we aimed to explore the inflammatory proteins that potentially serve as mediators between obesity and CKD by Mendelian randomization (MR) analysis, and to validate the findings by clinical research and animal experiments. METHODS: Two-step MR and mediation analyses were performed to assess the causal relationships between obesity-related traits and circulating inflammatory proteins and CKD. After identifying Oncostatin M (OSM) as the potential mediator, serum OSM levels of human participants with normal weight, overweight or obesity were assessed. Expression of OSM receptor (OSMR) in the human kidney was validated using publicly available scRNA-seq data. The protein expression and activation of OSMR in the kidneys of obese mice fed a high-fat diet (HFD) were validated by Western blotting. RESULTS: Circulating OSM level is a potential mediator between body mass index (BMI) and CKD, with a mediated proportion of 4.48%. In the clinical study, serum OSM levels were elevated in obese individuals and associated with both BMI and proteinuria. The scRNA-seq analysis found elevated OSMR expression in obese kidneys, with the highest expression level in endothelial cells. The in vivo experiment showed i
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Exosomes in diabetic kidney disease: pathogenesis, biomarker discovery, and emerging therapeutics-a comprehensive systematic review
Systematic Review on Chronic Kidney Disease, published in Ren Fail (2026) — summary generated from the PubMed abstract.
- 2026
Ren Fail - Level AMeta-analysisEurope PMC
Meta-analysis study of the therapeutic impact of Mesenchymal stem cells derived exosomes for chronic kidney diseases
Meta-analysis on Chronic Kidney Disease, published in Biochem Biophys Rep (2025) — summary generated from the PubMed abstract.
- 2025
Biochem Biophys Rep2 citations - Level ASystematic ReviewPubMed
Clinical Safety and Efficacy of Allogeneic Adipose Stem Cells: A Systematic Review of the Clinical Trials.
Systematic Review with a reported sample of 953 on Osteoarthritis, Chronic Kidney Disease, Scar, Autoimmune Research, published in Int J Mol Sci (2025) — summary generated from the PubMed abstract.
- 2025
- n = 953
Int J Mol Sci2 citations - Level ASystematic ReviewEurope PMC
Worldwide hotspots and trends in stem cell therapy for kidney disease in the last decade: a bibliometric and visualization analysis from 2015 to 2024
Systematic Review on Chronic Kidney Disease, Acute Kidney Injury, published in Front Immunol (2025) — summary generated from the PubMed abstract.
- 2025
Front Immunol2 citations - Level AMeta-analysisEurope PMC
Mesenchymal Stem Cells as Anti-Inflammatory Agents in Chronic Kidney Disease: A Systematic Review and Meta-Analysis
Meta-analysis on Chronic Kidney Disease, Chronic Inflammation, published in Cells (2025) — summary generated from the PubMed abstract.
- 2025
Cells - Level AMeta-analysisEurope PMC
Protective role of exosomes in renal ischemia-reperfusion injury: a systematic review and meta-analysis
Meta-analysis on Chronic Kidney Disease, Acute Kidney Injury, published in Front Pharmacol (2025) — summary generated from the PubMed abstract.
- 2025
Front Pharmacol1 citations